Cells enter a unique intermediate 4N stage, not 4N-G(1), after aborted mitosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mantel, Charlie | - |
dc.contributor.author | Guo, Ying | - |
dc.contributor.author | Lee, Man Ryul | - |
dc.contributor.author | Han, Myung Kwan | - |
dc.contributor.author | Rohrabough, Sara | - |
dc.contributor.author | Kim, Kye Seong | - |
dc.contributor.author | Broxmeyer, Hal E. | - |
dc.date.accessioned | 2022-10-07T10:41:10Z | - |
dc.date.available | 2022-10-07T10:41:10Z | - |
dc.date.created | 2022-08-26 | - |
dc.date.issued | 2008-02 | - |
dc.identifier.issn | 1538-4101 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/172152 | - |
dc.description.abstract | It is widely accepted that mammalian cells enter the next G(1)-phase (G(1)) with 4N DNA after slippage from prolonged drug-induced mitotic block caused by activation of the transient spindle checkpoint. Understanding cell fate after mitotic slippage (MS) has significant clinical importance. The conclusion the MS cells enter 4N-G(1) is based on morphology and mitotic cyclin destruction. Definitive biochemical evidence for G(1) is scarce or unconvincing, in part because of methods of protein extraction required for immunoblot analysis that cannot take into account the cell cycle heterogeneity of cell cultures. We used single-cell-intracellular-flow-cytometric analysis to further define important factors determining cell fate after MS. Results from human and mouse embryonic stem cells (ESC) that reenter polyploid cell cycles are compared to human somatic cells that die after MS. We conclude that phosphorylation status of pRb, p53, CDK1 and especially cyclin B1 levels are important for cell fate decision in MS cells, which occur in a unique, intervening, non-G(1), tetraploid subphase. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | LANDES BIOSCIENCE | - |
dc.title | Cells enter a unique intermediate 4N stage, not 4N-G(1), after aborted mitosis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kye Seong | - |
dc.identifier.doi | 10.4161/cc.7.4.5316 | - |
dc.identifier.scopusid | 2-s2.0-40549089207 | - |
dc.identifier.wosid | 000254364800012 | - |
dc.identifier.bibliographicCitation | CELL CYCLE, v.7, no.4, pp.484 - 492 | - |
dc.relation.isPartOf | CELL CYCLE | - |
dc.citation.title | CELL CYCLE | - |
dc.citation.volume | 7 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 484 | - |
dc.citation.endPage | 492 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.subject.keywordPlus | EMBRYONIC STEM-CELLS | - |
dc.subject.keywordPlus | DNA-DAMAGE | - |
dc.subject.keywordPlus | IN-VIVO | - |
dc.subject.keywordPlus | GROWTH ARREST | - |
dc.subject.keywordPlus | CYCLIN B1 | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | CHECKPOINT | - |
dc.subject.keywordPlus | P53 | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordAuthor | embryonic stem cell | - |
dc.subject.keywordAuthor | cell cycle | - |
dc.subject.keywordAuthor | cell cycle checkpoint | - |
dc.subject.keywordAuthor | polyploidy | - |
dc.subject.keywordAuthor | flow cytometry | - |
dc.subject.keywordAuthor | mitotic exit | - |
dc.identifier.url | https://www.tandfonline.com/doi/abs/10.4161/cc.7.4.5316 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.